Jpmorgan Chase & CO Corvus Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 49,556 shares of CRVS stock, worth $237,868. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,556
Previous 9,152
441.48%
Holding current value
$237,868
Previous $16,000
1531.25%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CRVS
# of Institutions
73Shares Held
30.4MCall Options Held
1.06MPut Options Held
84.3K-
Orbimed Advisors LLC San Diego, CA6.94MShares$33.3 Million0.86% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.56MShares$26.7 Million0.08% of portfolio
-
Samlyn Capital, LLC New York, NY4.53MShares$21.7 Million0.39% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$15.7 Million10.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$11.6 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $223M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...